ACTRN12615000098538已完成1 期
A single site, open label study to evaluate the pharmacodynamic effects of a single dose of oral anatabine citrate in healthy adult volunteers.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 10
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 65 Years（—）
- 性别
- All
入选标准
- •Males or females
- •In good general health
- •Aged between 18-65 years of age inclusive
- •Weighing between 45 and 100 kg
- •Laboratory tests within normal ranges or assessed not significant by the Clinical Investigator
排除标准
- •Current users of tobacco (cigarettes or smokeless)
- •Current user of anatabine citrate dietary supplements
- •Allergy to any of the product ingredients
- •Significant medical condition that could in the Investigator's opinion interfere with the study, or put the subject at significant risk
- •Participation in any drug or medical device study within 30 days of entering this study
研究者
相似试验
进行中（未招募）
1 期
Single dose study to evaluate how intravenous administered difelikefalin is absorbed by and cleared from Adolescents on HaemodialysisEUCTR2021-000894-94-ITVifor Fresenius Medical Care Renal Pharma Ltd.8
已完成
2 期
Single dose study to evaluate how intravenous administered difelikefalin is absorbed by and cleared from Adolescents on HaemodialysisPatients with chronic kidney disease undergoing hemodialysispruritus, kidney disease, pediatricCKD, associated pruritusLBCTR2022125201Vifor Fresenius Medical Care Renal Pharma Ltd.3
进行中（未招募）
不适用
An Open-label, Multi-centre Study to Assess the Pharmacokinetics, Efficacy and Safety of Biostate® in Subjects with Von Willebrand Disease.Von Willebrand DiseaseMedDRA version: 9.1Level: LLTClassification code 10047715Term: Von Willebrand's diseaseMedDRA version: 9.1Level: PTClassification code 10047715Term: Von Willebrand's diseaseEUCTR2008-004922-18-BGCSL Behring GmbH30
进行中（未招募）
1 期
A Study to Investigate the Pharmacokinetics (PK) and Safety of Risdiplam in Infants with Spinal Muscular AtrophySpinal Muscular Atrophy (SMA)MedDRA version: 20.1Level: LLTClassification code: 10041583Term: Spinal muscular atrophy unspecified Class: 10010331MedDRA version: 20.1Level: PTClassification code: 10041582Term: Spinal muscular atrophy Class: 100000004850MedDRA version: 20.1Level: LLTClassification code: 10051203Term: Spinal muscular atrophy congenital Class: 10010331CTIS2023-505602-42-00F. Hoffmann-La Roche AG10
进行中（未招募）
1 期
euromyelitis Optica Spectrum Disorder Inebilizumab Study in Children and AdolescentsEUCTR2021-003528-33-PLHorizon Therapeutics Ireland DAC15